Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5630156 | 0.91 | PARP1 (0.61) | PARP1PARP2 | |
| SCHEMBL12385320 | 0.91 | PARP1 (0.62) | PARP1PARP2 | |
| SCHEMBL467989 | 0.88 | PARP1 (0.71) | PARP1PARP2 | |
| SCHEMBL28263632 | 0.88 | KDM4E (0.50) | PARP1 | |
| SCHEMBL23581692 | 0.85 | PARP1 (0.66) | PARP1 | |
| SCHEMBL9756381 | 0.84 | KDM4E (0.51) | PARP1 | |
| SCHEMBL6836856 | 0.83 | PARP1 (0.51) | PARP1PARP2 | |
| SCHEMBL6841115 | 0.82 | PARP1 (0.50) | PARP1PARP2 | |
| SCHEMBL9125563 | 0.81 | RIPK1 (0.67) | PARP1 | |
| SCHEMBL25022851 | 0.80 | PARP1 (0.63) | PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022026-A1 | METHOD OF TREATING CANCER | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2012-01-26 | — | — | US | claimed |
| EP-2387403-A1 | METHOD OF TREATING CANCER | Academisch Medisch Centrum bij de Universiteit van Amsterdam (NL) | 2011-11-23 | — | — | EP | claimed |
| US-20110253692-A1 | Electrical heater for vehicle windshields and windows | SCHAUBLE RICHARD EGON | 2011-10-20 | — | — | US | claimed |
| WO-2010082821-A1 | METHOD OF TREATING CANCER | ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2010-07-22 | — | — | WO | claimed |
| US-20090270377-A1 | COMBINATION CANCER CHEMOTHERAPY | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2009-10-29 | — | — | US | claimed |
| WO-2007137000-A2 | COMBINATION CANCER CHEMOTHERAPY | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2007-11-29 | — | — | WO | claimed |
| US-20240105279-A1 | METHODS AND SYSTEMS EMPLOYING TARGETED NEXT GENERATION SEQUENCING FOR CLASSIFYING A TUMOR SAMPLE AS HAVING A LEVEL OF HOMOLOGOUS RECOMBINATION DEFICIENCY SIMILAR TO THAT ASSOCIATED WITH MUTATIONS IN BRCA1 OR BRCA2 GENES | Genomic Testing Cooperative, LCA (US) | 2024-03-28 | — | — | US | disclosed |
| WO-2024016014-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-4028009-A1 | TREATMENT OF HR DEFICIENT CANCER | The Francis Crick Institute Limited (GB) | 2022-07-20 | — | — | EP | disclosed |
| WO-2022057930-A1 | BENZIMIDAZOLE COMPOUND HAVING ENDOTHELIAL LIPASE INHIBITION EFFECT, AND APPLICATION | 盐城师范学院 | 2022-03-24 | — | — | WO | disclosed |
| US-11162095-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | INSTITUT CURIE (FR) | 2021-11-02 | — | — | US | disclosed |
| CN-113574171-A | Compositions and methods for treating cancer | IN8生物股份有限公司 | 2021-10-29 | — | — | CN | disclosed |
| US-20210322475-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE UAB RESEARCH FOUNDATION | 2021-10-21 | — | — | US | disclosed |
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
| CN-1733305-A | Anticancer implantation agent | KONG QINGZHONG (CN) | 2006-02-15 | — | — | CN | disclosed |
| US-20050227919-A1 | DNA damage repair inhibitors for the treatment of cancer | KUDOS PHARMACEUTICALS LIMITED | 2005-10-13 | — | — | US | disclosed |
| CN-1634586-A | Anti-cancer medicine composition | SHANDONG LANJIN BIOENGINEERING (CN) | 2005-07-06 | — | — | CN | disclosed |
| CN-1628849-A | Anticancer medicine composition | KONG QINGZHONG (CN) | 2005-06-22 | — | — | CN | disclosed |
| WO-2005053662-A1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | KUDOS PHARMACEUTICALS LIMITED (GB) | 2005-06-16 | — | — | WO | disclosed |
| WO-2003020698-A2 | PROTEIN TYROSINE KINASE INHIBITORS | PROCHON BIOTECH LTD. (IL) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11162095-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | PARP10, PARP1, PARP3 | PARP1 2/4885PARP2 5/4885 |
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | MRE11, PARP2, ERCC4 | PARP1 4/4885PARP2 2/4885 |
| US-20050227919-A1 | DNA damage repair inhibitors for the treatment of cancer | MRE11, ERCC4, PARP2 | PARP1 7/4885PARP2 3/4885 |
| US-20090270377-A1 | COMBINATION CANCER CHEMOTHERAPY | NCL, NSUN3, NOP58 | PARP1 118/4885PARP2 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.